A new approach at diabetic foot treatment: Phosphodiesterase 5 inhibitors
Diabetic foot (DF), is one of the most serious and prevalent complications of diabetes mellitus (DM). Disruption in tissue oxygenation due to atherosclerosis in peripheral veins has an important place in DF development. In recent years, phosphodiesterase type 5 (PDE5) inhibitor drugs like sildenafil...
Gespeichert in:
| Veröffentlicht in: | Medical hypotheses 2020-08, Vol.141, p.109694-109694, Article 109694 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 109694 |
|---|---|
| container_issue | |
| container_start_page | 109694 |
| container_title | Medical hypotheses |
| container_volume | 141 |
| creator | Buğday, Muhammet Serdar Öksüz, Ersoy |
| description | Diabetic foot (DF), is one of the most serious and prevalent complications of diabetes mellitus (DM). Disruption in tissue oxygenation due to atherosclerosis in peripheral veins has an important place in DF development. In recent years, phosphodiesterase type 5 (PDE5) inhibitor drugs like sildenafil, which cause peripheral vasodilation, are used commonly in cases of erectile dysfunction, pulmonary hypertension and cardiac insufficiency. In that sense, PDE5 inhibitors, which cause vasodilation in peripheral veins, can increase blood build up in tissues of patients with DF and its stand-alone usage or its usage with already used treatments can increase tissue healing speed and quality. |
| doi_str_mv | 10.1016/j.mehy.2020.109694 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2393619445</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0306987720303005</els_id><sourcerecordid>2393619445</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-ef25b1d422f835c31330ec3e866862f627bf1bd73d8bb921514321c7478ec8e03</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EoqXwAyyQl2xS_EjsBLGpKh6VKsEC1pbjTBRXTVxsF9S_J1EKS1Yjjc69mjkIXVMyp4SKu828heYwZ4QNi0IU6Qma0oyzhEkpT9GUcCKSIpdygi5C2BBCipTn52jCGadZwcQUrRa4g2-sdzvvtGmwjriyuoRoDa6dizh60LGFLt7jt8aFXeMqCyGC1wFwhm3X2NJG58MlOqv1NsDVcc7Qx9Pj-_IlWb8-r5aLdWJ4JmICNctKWqWM1TnPDKecEzAcciFywWrBZFnTspK8ysuyYDSjKWfUyFTmYHIgfIZux97-4s99f4pqbTCw3eoO3D4oxgsuaJGmWY-yETXeheChVjtvW-0PihI1KFQbNShUg0I1KuxDN8f-fdlC9Rf5ddYDDyMA_ZdfFrwKxkJnoLIeTFSVs__1_wDKrIFW</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2393619445</pqid></control><display><type>article</type><title>A new approach at diabetic foot treatment: Phosphodiesterase 5 inhibitors</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Buğday, Muhammet Serdar ; Öksüz, Ersoy</creator><creatorcontrib>Buğday, Muhammet Serdar ; Öksüz, Ersoy</creatorcontrib><description>Diabetic foot (DF), is one of the most serious and prevalent complications of diabetes mellitus (DM). Disruption in tissue oxygenation due to atherosclerosis in peripheral veins has an important place in DF development. In recent years, phosphodiesterase type 5 (PDE5) inhibitor drugs like sildenafil, which cause peripheral vasodilation, are used commonly in cases of erectile dysfunction, pulmonary hypertension and cardiac insufficiency. In that sense, PDE5 inhibitors, which cause vasodilation in peripheral veins, can increase blood build up in tissues of patients with DF and its stand-alone usage or its usage with already used treatments can increase tissue healing speed and quality.</description><identifier>ISSN: 0306-9877</identifier><identifier>EISSN: 1532-2777</identifier><identifier>DOI: 10.1016/j.mehy.2020.109694</identifier><identifier>PMID: 32315926</identifier><language>eng</language><publisher>United States: Elsevier Ltd</publisher><subject>Diabetes Mellitus ; Diabetic foot ; Diabetic Foot - drug therapy ; Erectile Dysfunction - drug therapy ; Humans ; Hypertension, Pulmonary ; Male ; Phosphodiesterase 5 Inhibitors ; Sildenafil Citrate</subject><ispartof>Medical hypotheses, 2020-08, Vol.141, p.109694-109694, Article 109694</ispartof><rights>2020 Elsevier Ltd</rights><rights>Copyright © 2020 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-ef25b1d422f835c31330ec3e866862f627bf1bd73d8bb921514321c7478ec8e03</citedby><cites>FETCH-LOGICAL-c356t-ef25b1d422f835c31330ec3e866862f627bf1bd73d8bb921514321c7478ec8e03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0306987720303005$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32315926$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Buğday, Muhammet Serdar</creatorcontrib><creatorcontrib>Öksüz, Ersoy</creatorcontrib><title>A new approach at diabetic foot treatment: Phosphodiesterase 5 inhibitors</title><title>Medical hypotheses</title><addtitle>Med Hypotheses</addtitle><description>Diabetic foot (DF), is one of the most serious and prevalent complications of diabetes mellitus (DM). Disruption in tissue oxygenation due to atherosclerosis in peripheral veins has an important place in DF development. In recent years, phosphodiesterase type 5 (PDE5) inhibitor drugs like sildenafil, which cause peripheral vasodilation, are used commonly in cases of erectile dysfunction, pulmonary hypertension and cardiac insufficiency. In that sense, PDE5 inhibitors, which cause vasodilation in peripheral veins, can increase blood build up in tissues of patients with DF and its stand-alone usage or its usage with already used treatments can increase tissue healing speed and quality.</description><subject>Diabetes Mellitus</subject><subject>Diabetic foot</subject><subject>Diabetic Foot - drug therapy</subject><subject>Erectile Dysfunction - drug therapy</subject><subject>Humans</subject><subject>Hypertension, Pulmonary</subject><subject>Male</subject><subject>Phosphodiesterase 5 Inhibitors</subject><subject>Sildenafil Citrate</subject><issn>0306-9877</issn><issn>1532-2777</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtOwzAQRS0EoqXwAyyQl2xS_EjsBLGpKh6VKsEC1pbjTBRXTVxsF9S_J1EKS1Yjjc69mjkIXVMyp4SKu828heYwZ4QNi0IU6Qma0oyzhEkpT9GUcCKSIpdygi5C2BBCipTn52jCGadZwcQUrRa4g2-sdzvvtGmwjriyuoRoDa6dizh60LGFLt7jt8aFXeMqCyGC1wFwhm3X2NJG58MlOqv1NsDVcc7Qx9Pj-_IlWb8-r5aLdWJ4JmICNctKWqWM1TnPDKecEzAcciFywWrBZFnTspK8ysuyYDSjKWfUyFTmYHIgfIZux97-4s99f4pqbTCw3eoO3D4oxgsuaJGmWY-yETXeheChVjtvW-0PihI1KFQbNShUg0I1KuxDN8f-fdlC9Rf5ddYDDyMA_ZdfFrwKxkJnoLIeTFSVs__1_wDKrIFW</recordid><startdate>202008</startdate><enddate>202008</enddate><creator>Buğday, Muhammet Serdar</creator><creator>Öksüz, Ersoy</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202008</creationdate><title>A new approach at diabetic foot treatment: Phosphodiesterase 5 inhibitors</title><author>Buğday, Muhammet Serdar ; Öksüz, Ersoy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-ef25b1d422f835c31330ec3e866862f627bf1bd73d8bb921514321c7478ec8e03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Diabetes Mellitus</topic><topic>Diabetic foot</topic><topic>Diabetic Foot - drug therapy</topic><topic>Erectile Dysfunction - drug therapy</topic><topic>Humans</topic><topic>Hypertension, Pulmonary</topic><topic>Male</topic><topic>Phosphodiesterase 5 Inhibitors</topic><topic>Sildenafil Citrate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Buğday, Muhammet Serdar</creatorcontrib><creatorcontrib>Öksüz, Ersoy</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Medical hypotheses</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Buğday, Muhammet Serdar</au><au>Öksüz, Ersoy</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A new approach at diabetic foot treatment: Phosphodiesterase 5 inhibitors</atitle><jtitle>Medical hypotheses</jtitle><addtitle>Med Hypotheses</addtitle><date>2020-08</date><risdate>2020</risdate><volume>141</volume><spage>109694</spage><epage>109694</epage><pages>109694-109694</pages><artnum>109694</artnum><issn>0306-9877</issn><eissn>1532-2777</eissn><abstract>Diabetic foot (DF), is one of the most serious and prevalent complications of diabetes mellitus (DM). Disruption in tissue oxygenation due to atherosclerosis in peripheral veins has an important place in DF development. In recent years, phosphodiesterase type 5 (PDE5) inhibitor drugs like sildenafil, which cause peripheral vasodilation, are used commonly in cases of erectile dysfunction, pulmonary hypertension and cardiac insufficiency. In that sense, PDE5 inhibitors, which cause vasodilation in peripheral veins, can increase blood build up in tissues of patients with DF and its stand-alone usage or its usage with already used treatments can increase tissue healing speed and quality.</abstract><cop>United States</cop><pub>Elsevier Ltd</pub><pmid>32315926</pmid><doi>10.1016/j.mehy.2020.109694</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0306-9877 |
| ispartof | Medical hypotheses, 2020-08, Vol.141, p.109694-109694, Article 109694 |
| issn | 0306-9877 1532-2777 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2393619445 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Diabetes Mellitus Diabetic foot Diabetic Foot - drug therapy Erectile Dysfunction - drug therapy Humans Hypertension, Pulmonary Male Phosphodiesterase 5 Inhibitors Sildenafil Citrate |
| title | A new approach at diabetic foot treatment: Phosphodiesterase 5 inhibitors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T18%3A48%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20new%20approach%20at%20diabetic%20foot%20treatment:%20Phosphodiesterase%205%20inhibitors&rft.jtitle=Medical%20hypotheses&rft.au=Bu%C4%9Fday,%20Muhammet%20Serdar&rft.date=2020-08&rft.volume=141&rft.spage=109694&rft.epage=109694&rft.pages=109694-109694&rft.artnum=109694&rft.issn=0306-9877&rft.eissn=1532-2777&rft_id=info:doi/10.1016/j.mehy.2020.109694&rft_dat=%3Cproquest_cross%3E2393619445%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2393619445&rft_id=info:pmid/32315926&rft_els_id=S0306987720303005&rfr_iscdi=true |